Search Results - "Palomares, Laida Cuevas"

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75‐year‐olds newly diagnosed with multiple myeloma by Pérez‐Persona, Ernesto, Oiartzabal‐Ormategui, Itziar, Herraez, Susana, Menchaca, Carmen, Cuevas‐Palomares, Laida, Santamaría‐López, Ana, Díez‐Angulo, Rosana, Robles‐Castro, Diego, Miguel‐Sánchez, Carlos, Gabilondo‐Jalón, Miren, Pisón‐Herrero, Carlos, Unamunzaga‐Cilaurren, Ariane, Vega González‐Viñaspre, Ana, Salcedo‐Cuesta, Laura, Mendizabal‐Abad, Arantza, Guinea de Castro, José María

Get full text

PB2341: EARLY MORTALITY VARIABLES IN PATIENTS OLDER THAN 75 YEARS WITH DIFFUSE LARGE B‐CELL LYMPHOMA by Pérez, Mónica Fernández, Palomares, Laida Cuevas, Persona, Ernesto Pérez, De Ocariz, Xabier Gutierrez Lopez

Get full text

Treatment burden in multiple myeloma according to comorbidity in real life by Pérez Persona, Ernesto, Oiartzabal Ormategui, Itziar, Cuevas Palomares, Laida, Santamaría López, Ana, Robles de Castro, Diego, Miguel de Sánchez, Carlos, Gabilondo Jalón, Miren, Pisón Herrero, Carlos, Unamunzaga Cilaurren, Ariane, Vega González de Viñaspre, Ana, Guinea de Castro, Jose María

Get full text

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY by Palomares, Laida Cuevas, Pérez, Ernesto, Cilaurren, Ariane Unamunzaga, De Ocariz, Xabier Gutierrez Lopez, Ureña, Buenaventura Buendia, Fernández, Carmen Molinillo, Ibarrondo, Begoña Benito, Osua, Ana Cordero, Delgado, Beatriz Benitez, Moralejo, Miguel Andrés, Albás, Juan García, Castro, Jose Guinea

Get full text

Ultrafast 30-min infusion of a rituximab biosimilar (Truxima) by Pérez-Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutiérrez López de Ocáriz, Xabier, Buendía Ureña, Buenaventura, Vega González de Viñaspre, Ana, Benito Ibarrondo, Begoña, Molinillo Fernández, María Carmen, Cordero Osúa, Ana, Benítez Delgado, Beatriz, García Albás, Juan José, Andrés Moralejo, Miguel Ángel, Guinea de Castro, José María

“…In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for…”
Get full text

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones by Pierola, Ana Alfonso, Ariceta, Beñat, Vilas-Zornoza, Amaia, Aguirre-Ruiz, Paula, Sarvide, Sarai, San-Martin, Patxi, Fortuño, Maria-Antonia, Simoes, Catia, Burgos, Leire, Larrayoz, Maria Jose, Chillon, Carmen, Arce, Olga, Bernal Del Castillo, Teresa, Colorado, Mercedes, Cuevas Palomares, Laida, Marchante, Inmaculada, Mateos, Maria Carmen, Olave, Mayte, Pérez-Simón, Jose A., Calasanz, Maria Jose, Garcia-Sanz, Ramon, Paiva, Bruno, Montesinos, Pau, Prosper, Felipe

“…Introduction:Despite recent advances in AML treatment, patients continue to relapse and become chemotherapy resistant, leading to poor long-term overall…”
Get full text

Txagorrapid: Ultrarapid infusion in 30 minutes of the biosimilar of rituximab truxima—A cohort study by Perez Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutierrez López de Gutierrez, Xabier, Buendía Ureña, Buenaventura, Molinillo Fernández, Carmen Luisa, Benito Ibarrondo, Begoña, Cordero Osua, Ana Isabel, Benítez Delgado, Beatriz, Andrés Moralejo, Miguel Angel, García Albás, Juan José, Guinea de Castro, José María

“…e13638 Background: Rituximab (anti-CD20 Ab) is the cornerstone of the treatment of non-Hodgkin B lymphomas. Infusion-related reactions (IRR) are the most…”
Get full text

Treatment Burden in Patients with Multiple Myeloma According to Comorbidity by Pérez Persona, Ernesto, Unamunzaga Cilaurren, Ariane, Vega Gonzalez de Viñaspre, Ana, Oiartzabal Ormategui, Itziar, Santamaría Lopez, Ana, Cuevas Palomares, Laida, Robles de Castro, Diego, de Miguel Sanchez, Carlos, Gabilondo Jalón, Miren, Pereda Vicandi, Angel, Mendizábal, Arantza, Guinea de Castro, Jose María

“…▪ Introduction: Over the last few years, novel agents-based combinations have been incorporated into the treatment of MM patients, particularly in relapse…”
Get full text

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry by Martínez, Pilar, Palanques Pastor, Tomás, Lopez Lorenzo, Jose Luiz, Cornago Navascués, Javier, Rodriguez-Macías, Gabriela, Cano, Isabel, Arnan Sangerman, Montserrat, Vidriales, María-Belén, Algarra, Jesús Lorenzo, Foncillas, Maria Angeles, Herrera Puente, Pilar, Botella, Carmen, Vives, Susana, Figuera Alvarez, Angela, Cuevas Palomares, Laida, Sobas, Marta, Contento-Gonzalo, Alejandro, Cuello, Rebeca, Amutio Diez, María Elena, De Miguel, Maria Dunia, Navas, Begoña, Bergua Burgues, Juan Miguel, Bernal del Castillo, Teresa, Mateos Rodríguez, María Carmen, de Cabo López, Erik, Franco Villegas, Ana Carolina, García-Boyero, Raimundo, Escolano Escobar, Cristian, Seri, Cristina, Cervero, Carlos, Roldán Pérez, Alicia, Hermosin, Maria Lourdes, Cervera, Marta, Olave, María Teresa, Villafuerte Gutierrez, Paola Sandra, De Laiglesia, Almudena, Serrano, Josefina, Najera Irazu, María Josefa, Piñana Sanchez, Jose Luis, Sanz, Miguel Ángel, Martinez-Lopez, Joaquin, Montesinos, Pau

“…SARS-CoV-2 infection can impact survival of patients with acute myeloid leukemia (AML). International experts recommend considering delaying or stopping AML…”
Get full text